Several people in this forum have used Provigil during tx for increased energy & concentration. The FDA issued the following warning late last week.
I used Provigil for 24 weeks during the Prove 3 trial that ended for me two weeks ago and have not been taken off it yet. Since stopping tx I've been jittery and have developed a small patch of rough rash on my temples that won't go away. I have my 2 week post tx appointment this AM and will address this. FYI....
Mike
_____________________________________________________________________________________________
FDA and Cephalon notified healthcare professionals of Warnings added to
prescribing information for Provigil (modafinil). Provigil is indicated
to improve wakefulness in adult patients with excessive sleepiness
associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome,
and shift work sleep disorder. The revised prescribing information
updates safety information to include warnings regarding serious rash,
including Stevens-Johnson Syndrome (SJS) and hypersensitivity reactions,
and psychiatric symptoms. Rare cases of serious or life-threatening
rash, including Toxic Epidermal Necrolysis, and Drug Rash with
Eosinophilia and Systemic Symptoms have been reported in adults and
children in worldwide postmarketing experience. Angioedema and
multi-organ hypersensitivity reactions have also been reported in
postmarketing experience.
Physicians should instruct their patients to immediately discontinue the
use of Provigil and contact them if a rash or other hypersensitivity
reaction occurs. Healthcare professionals and consumers should also be
aware that Provigil is not approved for use in pediatric patients for
any indication. In addition, psychiatric adverse experiences (including
anxiety, mania, hallucinations, and suicidal ideation) have been
reported in patients treated with Provigil. Caution should be exercised
when Provigil is given to patients with a history of psychosis,
depression, or mania.
Additional labeling revisions were made to the CLINICAL PHARMACOLOGY,
PRECAUTIONS, and PATIENT PACKAGE INSERT sections. Read the complete
MedWatch 2007 Safety Summary including a link to the manufacturer's Dear
Healthcare Professional Letter and the revised prescribing information
at: http://www.fda.gov/medwatch/safety/2007/safety07.htm#Provigil